These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 99837)

  • 21. Immobilization of the plasminogen activator streptokinase and its fibrinolytic effects in vivo.
    Mercer LC; Everse KE; Holmes AW; Everse J
    Thromb Res; 1978 Dec; 13(6):931-40. PubMed ID: 107613
    [No Abstract]   [Full Text] [Related]  

  • 22. Type 1 plasminogen activator inhibitor and its potential influence on thrombolytic therapy.
    Loskutoff DJ
    Semin Thromb Hemost; 1988 Jan; 14(1):100-9. PubMed ID: 3127883
    [No Abstract]   [Full Text] [Related]  

  • 23. Plasma inhibitors of the Hageman factor dependent pathways.
    Schreiber AD
    Semin Thromb Hemost; 1976 Jul; 3(1):32-51. PubMed ID: 799348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factor XIIa is a kinetically favorable plasminogen activator.
    Schousboe I; Feddersen K; Røjkjaer R
    Thromb Haemost; 1999 Sep; 82(3):1041-6. PubMed ID: 10494761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the contact system in fibrinolysis.
    Kluft C; Dooijewaard G; Emeis JJ
    Semin Thromb Hemost; 1987 Jan; 13(1):50-68. PubMed ID: 3105061
    [No Abstract]   [Full Text] [Related]  

  • 26. Small synthetic peptides with affinity for proteases in coagulation and fibrinolysis: an overview.
    Claeson G; Aurell L
    Ann N Y Acad Sci; 1981; 370():798-811. PubMed ID: 6455958
    [No Abstract]   [Full Text] [Related]  

  • 27. A new function for activated protein C: activated protein C prevents inhibition of plasminogen activators by releasate from mononuclear leukocytes--platelet suspensions stimulated by phorbol diester.
    Taylor FB; Lockhart MS
    Thromb Res; 1985 Jan; 37(1):155-64. PubMed ID: 3920776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Endothelial cells and vascular hemostasis].
    Levin EG; Hanano M
    Nihon Rinsho; 1992 Feb; 50(2):303-6. PubMed ID: 1319512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type 1 plasminogen activator inhibitor.
    Loskutoff DJ; Sawdey M; Mimuro J
    Prog Hemost Thromb; 1989; 9():87-115. PubMed ID: 2492381
    [No Abstract]   [Full Text] [Related]  

  • 30. Activation and consumption of Hageman factor in the anaphylactic shock of the rat.
    Fésüs L; Csaba B; Muszbek L
    Int Arch Allergy Appl Immunol; 1976; 51(4):496-507. PubMed ID: 965106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human fibroblasts produce inhibitor directed against plasminogen activator when treated with glucocorticoids.
    Crutchley DJ; Conanan LB; Maynard JR
    Ann N Y Acad Sci; 1981; 370():609-16. PubMed ID: 6455956
    [No Abstract]   [Full Text] [Related]  

  • 32. Purification of a plasminogen activator inhibitor indistinguishable from alpha1-antitrypsin and an urokinase inhibitor in pregnancy plasma.
    Clemmensen I; Thorsen S; Müllertz S
    Haemostasis; 1976; 5(4):218-30. PubMed ID: 826461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases.
    Kummer JA; Abbink JJ; de Boer JP; Roem D; Nieuwenhuys EJ; Kamp AM; Swaak TJ; Hack CE
    Arthritis Rheum; 1992 Aug; 35(8):884-93. PubMed ID: 1379429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood.
    Sprengers ED; Akkerman JW; Jansen BG
    Thromb Haemost; 1986 Jun; 55(3):325-9. PubMed ID: 3092389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibrinolytic properties of activated FXII.
    Braat EA; Dooijewaard G; Rijken DC
    Eur J Biochem; 1999 Aug; 263(3):904-11. PubMed ID: 10469157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between factor XII, von Willebrand factor and postoperative deep vein thrombosis.
    Nilsson T; Mellbring G; Hedner U
    Acta Chir Scand; 1986 May; 152():347-9. PubMed ID: 3090810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on prekallikrein of bovine plasma. II. Activation of prekallikrein with proteinases and properties of kallikrein activated by bovine Hageman factor.
    Takahashi H; Nagasawa S; Suzuki T
    J Biochem; 1980 Jan; 87(1):23-34. PubMed ID: 6766924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anti-activator inhibitors of plasminogen].
    Juhan-Vague I; Alessi MC; Aillaud MF
    Ann Biol Clin (Paris); 1987; 45(2):202-6. PubMed ID: 3113299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contact activation of Hageman factor and the interaction of Hageman factor and plasma thromboplastin antecedent.
    Haanen C; Morselt G; Schoenmakers J
    Thromb Diath Haemorrh; 1967 May; 17(3-4):307-20. PubMed ID: 5626768
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibition of the activation of Hageman factor (factor XII) by extracts of Schistosoma mansoni.
    Foster CB; Flanigan TP; DeStigter KK; Blanton R; Dumenco LL; Gallagher C; Ratnoff OD
    J Lab Clin Med; 1992 Nov; 120(5):735-9. PubMed ID: 1431502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.